Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025, mainly due to the absence of a $50 million payment from Nestlé related to the VOWST sale. The company is progressing its live biotherapeutic pipeline, including SER-155 for immune checkpoint inhibitor-related enterocolitis and bloodstream infection prevention in blood cancer patients, and SER-603 for inflammatory bowel disease. Clinical data from an investigator-sponsored trial of SER-155 is expected soon, which could expand its therapeutic applications. Seres is actively seeking partnerships and funding to support further development and extend its cash runway beyond Q3 2026.
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
